Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study of SGM-1019 in Healthy Subjects

Next Previous
Search
Trial Profile

A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study of SGM-1019 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGM 1019 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Second Genome

    • Most Recent Events

    • 09 Apr 2018 Results (safety and pharmacodynamics) presented in a Second Genome media release.
    • 09 Apr 2018 According to a Second Genome media release, preclinical data and results from this trial will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2018 (on Friday, 13 Apr 2018).
    • 20 Jan 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top